Researchers develop drug to block METTL1 enzyme in cancer cells
Scientists have created a new inhibitor called STM9005 that targets the METTL1 enzyme to treat various solid and blood cancers.
New drug blocks cell growth
Treatment with STM9005 stops cancer cells from multiplying in laboratory models. This compound also forces changes in how cells differentiate and alters their cell cycle progression.
Drug reduces specific RNA marks
The therapy causes a selective drop in m7G modifications on certain transfer RNAs. Lower expression levels of these molecules subsequently impact the translation of oncogenic messenger RNAs.
Mice show longer survival times
Giving STM9005 to mice with tumors from different tissue origins impaired tumor growth significantly. These animals lived longer compared to those that did not receive the treatment.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.